tmax, Canadian approach [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2008-11-24 14:53 (6051 d 07:49 ago) – Posting: # 2788
Views: 23,225

Dear Helmut,

❝ Sometimes I forget the true country of the brave and the free - Canada...


Brave and free already since a long time ago regarding their outstanding handling of Cmax :ok:.

[...] where AUCReftmax for a test product is defined as the area under the curve to the time of the maximum concentration of the reference product, calculated for each study subject.'

❝ No fiddling around with median tmax, no search for a reference value in the reference's SmPC - just straight out of the study,


This is valuable, but is not easily extended to replicate designs.

but:


❝ Whatever approach we will choose, IMHO it will be very difficult to show BE for rapid onset drugs if partial areas are a main target parameter due to it's high variability.


I wonder why they haven't adopted the Cmax/AUC metric, which is reported to have better properties regarding variability. Especially because L. Endrenyi (frequent speaker on TPD meetings) from Toronto (is in Canada as far as I know ;-) ) is one of its inventors and strong advocats. :ponder:

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
37 visitors (0 registered, 37 guests [including 17 identified bots]).
Forum time: 23:43 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5